The Potential of ENV-101 in Treating Idiopathic Pulmonary Fibrosis and Cancer | 2024 ATS

Editors spoke with Endeavor BioMedicines CEO John Hood about ENV-101, a novel Hedgehog inhibitor, in which he shared results on from a recent phase 2 clinical trial. Unlike current inhibitors used in cancer treatment, ENV-101 offers improved tolerability with fewer severe muscle spasms. The drug targets the Hedgehog signaling pathway, implicated in both idiopathic pulmonary fibrosis (IPF) and some cancers. Following promising phase two results, Endeavor plans a phase two B trial this fall, aiming to begin phase three trials by 2026 for potential FDA approval.

[@HelenAngelo-pc7nw]

See more...at dr osuma for health issues